Log in

Elite Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:ELTP)

+0.00 (+0.62 %)
(As of 10/17/2019 06:01 AM ET)
Today's Range
Now: $0.08
50-Day Range
MA: $0.08
52-Week Range
Now: $0.08
Volume428,190 shs
Average Volume1.44 million shs
Market Capitalization$67.55 million
P/E RatioN/A
Dividend YieldN/A
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products segments. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 15mg and 30mg capsules, and 37.5mg tablets for the treatment of bariatrics under Adipex-P brand name; Lodrane D immediate release capsules for OTC allergy treatment; Methadone HCl 10mg tablets for pains under the Dolophine name; and Hydromorphone HCl 8mg tablets for pains under the Dilaudid name. The company also provides Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril name; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia name; Isradipine 2.5mg and 5mg capsules for cardiovascular diseases; Hydroxyzine HCl 10mg, 25mg, and 50mg tablets for antihistamine treatment under Atarax and Vistaril brand names; Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone name; and Trimipramine Maleate Immediate Release 25mg, 50mg, and 100mg antidepressant capsules under the Surmontil brand, as well as SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; manufacturing and supply agreement with The PharmaNetwork LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA. The company was founded in 1984 and is headquartered in Northvale, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ELTP



Sales & Book Value

Annual Sales$7.57 million


Net Income$-9,280,000.00


Market Cap$67.55 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive ELTP News and Ratings via Email

Sign-up to receive the latest news and ratings for ELTP and its competitors with MarketBeat's FREE daily newsletter.

Elite Pharmaceuticals (OTCMKTS:ELTP) Frequently Asked Questions

What is Elite Pharmaceuticals' stock symbol?

Elite Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELTP."

How were Elite Pharmaceuticals' earnings last quarter?

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) released its quarterly earnings data on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company earned $1.60 million during the quarter. Elite Pharmaceuticals had a negative return on equity of 1,783.76% and a negative net margin of 83.47%. View Elite Pharmaceuticals' Earnings History.

When is Elite Pharmaceuticals' next earnings date?

Elite Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Elite Pharmaceuticals.

Has Elite Pharmaceuticals been receiving favorable news coverage?

News articles about ELTP stock have trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Elite Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Elite Pharmaceuticals.

Who are some of Elite Pharmaceuticals' key competitors?

What other stocks do shareholders of Elite Pharmaceuticals own?

Who are Elite Pharmaceuticals' key executives?

Elite Pharmaceuticals' management team includes the folowing people:
  • Mr. Nasrat Hakim, Chairman, CEO & Pres (Age 58)
  • Mr. Carter J. Ward, CFO, Chief Accounting Officer, Treasurer & Sec. (Age 55)
  • Mr. Douglas Plassche, Exec. VP of Operations (Age 55)
  • Dr. George Kenneth Smith J.D., M.B.A., Ph.D., VP of Legal
  • Ms. Dianne Will, VP of Investor Relations & Corp. Affairs

How do I buy shares of Elite Pharmaceuticals?

Shares of ELTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Elite Pharmaceuticals' stock price today?

One share of ELTP stock can currently be purchased for approximately $0.08.

How big of a company is Elite Pharmaceuticals?

Elite Pharmaceuticals has a market capitalization of $67.55 million and generates $7.57 million in revenue each year. Elite Pharmaceuticals employs 43 workers across the globe.View Additional Information About Elite Pharmaceuticals.

What is Elite Pharmaceuticals' official website?

The official website for Elite Pharmaceuticals is http://www.elitepharma.com/.

How can I contact Elite Pharmaceuticals?

Elite Pharmaceuticals' mailing address is 165 LUDLOW AVENUE, NORTHVALE NJ, 07647. The specialty pharmaceutical company can be reached via phone at 201-750-2646 or via email at [email protected]

MarketBeat Community Rating for Elite Pharmaceuticals (OTCMKTS ELTP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Elite Pharmaceuticals and other stocks. Vote "Outperform" if you believe ELTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELTP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel